Harvard Bioscience Inc (HBIO)vsWest Pharmaceutical Services Inc (WST)
HBIO
Harvard Bioscience Inc
$8.03
-1.47%
HEALTHCARE · Cap: $37.33M
WST
West Pharmaceutical Services Inc
$346.23
+0.58%
HEALTHCARE · Cap: $23.93B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 3689% more annual revenue ($3.33B vs $87.81M). WST leads profitability with a 17.0% profit margin vs -11.9%. HBIO appears more attractively valued with a PEG of 1.31. WST earns a higher WallStSmart Score of 61/100 (C+).
HBIO
Hold36
out of 100
Grade: F
WST
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HBIO.
Margin of Safety
-46.2%
Fair Value
$168.33
Current Price
$346.23
$177.90 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -147.1% — below average capital efficiency
Earnings declined 80.3%
Trading at 8.2x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : HBIO
Revenue growth of 11.1% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : HBIO
The primary concerns for HBIO are Market Cap, Piotroski F-Score, Return on Equity. Debt-to-equity of 5.96 is elevated, increasing financial risk.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.
Key Dynamics to Monitor
HBIO profiles as a turnaround stock while WST is a mature play — different risk/reward profiles.
HBIO carries more volatility with a beta of 1.49 — expect wider price swings.
WST is growing revenue faster at 13.8% — sustainability is the question.
WST generates stronger free cash flow (81M), providing more financial flexibility.
Bottom Line
WST scores higher overall (61/100 vs 36/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harvard Bioscience Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?